#CYLD
RRIDs were included in this in EMBO Reports paper. Thanks for making your methods matter! #OpenScience #accelerateopenscience #methodsmatter
Caspase-3 cleaves CYLD to restrict interferon signaling during mitochondrial apoptosis
Read the full paper: Caspase-3 cleaves CYLD to restrict interferon signaling during mitochondrial apoptosis
doi.org
October 9, 2026 at 7:04 AM
Summer @labsoap.bsky.social papers : all about cell deaths

1. LUBAC and pyroptosis @cp-iscience.bsky.social
www.cell.com/iscience/ful...
2. CYLD and mitochondrial death @emboreports.org
link.springer.com/article/10.1...
3. CK1a and cGAS/STING #CellDeathDiff
www.nature.com/articles/s41...
September 1, 2026 at 4:33 AM
Happy to share our mini-review on CYLD, its role at the crossroads of life and death decisions, and its regulation through PTMs. @nbidere.bsky.social #YanisMace @labsoap.bsky.social @insermgrandouest.bsky.social
www.frontiersin.org/journals/cel...
Frontiers | The good, the bad, and the modified: CYLD’s post-translational tale
www.frontiersin.org
April 9, 2025 at 9:46 AM
🎥 Watch the relevant video: youtu.be/EcGFlVL7Tjo
Tiny worm shows how CYLD keeps neurons healthy during aging
YouTube video by AJE Video Bytes
youtu.be
July 20, 2026 at 4:54 PM
“Ben Meiselas @meiselasb.bsky.social reports on the latest effort by the Trump administration and the GOP to change the identity and background of the killer of Charlie Kirk to fit their original narrative.” -MTN

m.youtube.com/watch?v=CylD...
PANICKING GOP tries DESPERATELY to CHANGE IDENTITY of KILLER
YouTube video by MeidasTouch
m.youtube.com
September 14, 2025 at 2:32 PM
and dubious reporting
www.youtube.com/watch?v=CylD...
PANICKING GOP tries DESPERATELY to CHANGE IDENTITY of KILLER
YouTube video by MeidasTouch
www.youtube.com
September 14, 2025 at 4:17 PM
This paper highlights the role of CYLD in splenic marginal zone lymphoma pathogenesis. CYLD downregulation leads to NF-κB pathway hyperactivation, ⬆️#SMZL cell proliferation & resistance to ibrutinib. CYLD could be a novel target for stratification & personalized interventions 👉https://bit.ly/3RgacV8
April 21, 2025 at 8:30 AM
Fantastic talk from @derm-scientist.bsky.social about CYLD cutaneous syndrome at the 2024 Skin@Bath symposium.
December 13, 2024 at 10:24 AM
Swing! And a Miss! 🤣👌🤣

youtube.com/watch?v=CylD...
PANICKING GOP tries DESPERATELY to CHANGE IDENTITY of KILLER
YouTube video by MeidasTouch
youtube.com
September 14, 2025 at 2:04 PM
Cancer Rares : une voie moléculaire inattendue ciblable dans le Syndrome Cutané de CYLD
Cancer Rares : une voie moléculaire inattendue ciblable dans le Syndrome Cutané de CYLD
Dans une étude intégrative publiée dans Journal of Investigative Dermatology, les scientifiques de l’équipe Génomique Translationnelle du Cancer dirigée par Sergey Nikolaev au sein de l'UMR-S 981 (Inserm/UPSaclay/Gustave Roussy, Villejuif), en collaboration avec l'équipe du Professeur Daniel Hohl au CHUV (Lausanne, Suisse), ont analysé le paysage moléculaire de 50 tumeurs issues du Syndrome Cutané de CYLD (CCS), un trouble génétique rare. Ces tumeurs, caractérisées par une très faible charge mutationnelle, présentent des mutations des gènes CYLD, DNMT3A et BCOR.   Le travail a révélé une vulnérabilité oncogénique majeure et précise dans les cylindromes, les tumeurs caractéristiques du CCS : l'activation spécifique de la voie NF-κB non canonique. Cette activation, confirmée par des analyses d'expression et immunohistochimiques (forte expression nucléaire de NFKB2/p52), met en lumière un moteur essentiel de la formation tumorale. L’identification de cette branche non canonique ouvre la voie à l'exploration de thérapies ciblées, une avancée significative par rapport à l’échec des inhibiteurs non spécifiques du NF-κB testés antérieurement. De plus, le profilage par méthylation a résolu l’énigme de l’origine cellulaire de ces tumeurs. Les cylindromes (Groupe 1) proviennent des glandes sudoripares apocrines, tandis que les trichoépithéliomes (Groupe 2) se regroupent avec le carcinome basocellulaire (BCC).   Ces résultats démontrent que la cellule d’origine dicte le phénotype tumoral, malgré la même mutation initiale de CYLD, et soulignent la nécessité de cibler l'axe NF-κB non canonique pour le traitement du CCS.   -> Contact : sergey.nikolaev@gustaveroussy.fr
www.jidonline.org
December 3, 2025 at 10:32 PM
The tumor suppressor CYLD acts as a deubiquitinase for mTOR to constrain its activity
www.biorxiv.org/content/10.1...
The tumor suppressor CYLD acts as a deubiquitinase for mTOR to constrain its activity
Proper control of mTOR (mechanistic/mammalian target of rapamycin) signaling is relevant for health, disease and ageing. Information from intra- and extra-cellular signaling cues is transmitted to mTO...
www.biorxiv.org
September 15, 2025 at 7:00 PM
Support INDEPENDENT news. 👉👀 youtube.com/watch?v=CylD...
PANICKING GOP tries DESPERATELY to CHANGE IDENTITY of KILLER
YouTube video by MeidasTouch
youtube.com
September 14, 2025 at 3:06 PM
Excited to share our latest work from first author Patrick Woida. Using a novel surface display platform for expression of split TurboID, we discovered that CYLD is recruited to the Listeria surface via the effector InlC and that it supports cell-to-cell spread www.biorxiv.org/content/10.6...
www.biorxiv.org
February 24, 2026 at 11:45 AM
Fabulous work by Aimiliani Konstantinou, together with three other #UBIMOTIF members Alicia Córdova-Pérez, Julia K. Varga & Maximilian Vieler. #CYLD, #USP7, #USP11, #USP20, #USP22, #USP33
September 22, 2025 at 2:08 PM
The authors included RRIDs in their in Clinical Cancer Research paper! Thanks for making your methods matter! #BetterScience #ReproducibleResearch #OpenResearch
Genomic enrichment and functional impact of TP53 and CYLD alterations in recurrent and metastatic HPV-associated head and neck cancer
Read the full paper: Genomic enrichment and functional impact of TP53 and CYLD alterations in recurrent and metastatic HPV-associated head and neck cancer
doi.org
March 12, 2026 at 7:01 AM
RRIDs were included in this None paper. Thanks for making your methods matter! #RRID #RRID #RRID
The tumor suppressor CYLD acts as a deubiquitinase for mTOR to constrain its activity
doi.org
September 10, 2025 at 7:00 AM